drugset / Trial / NCT01792713

Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis

NCT01792713

Phase 2 Completed 70 enrolled Spirig Pharma Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Investigation aimed to explore the efficacy of a topical Sertaconazole cream 2% in patients with skin alterations associated with atopic dermatitis

Timeline

Start
2013-02
Primary completion
2013-09
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sertaconazole Small molecule 2 % Topical

Indications